Searching journal content for adrenocortical carcinoma (as phrase) in full text.

Displaying results 1-10 of 88
For checked items
  1. ...adrenocortical carcinoma and neuroendocrine tumors. We present the challenges and the opportunities of using immune checkpoint inhibitors against these endocrine malignancies, highlighting the breakthroughs and pitfalls that have recently emerged. Introduction Immune checkpoint inhibitors are agents ~~~
  2. ...adrenocortical carcinoma . International Journal of Endocrine Oncology 1 173 – 182 . ( doi:10.2217/ije.14.13 ) ↵ Azad A , Yin Lim S , D’Costa Z , Jones K , Diana A , Sansom OJ , Kruger P , Liu S , McKenna WG , Dushek O et al. 2017 PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma ~~~
  3. ...adrenocortical carcinoma (ACC), but this is a life-threatening malignant tumor (Skogseid et al. 1995, Gibril et al. 2004, Waldmann et al. 2007). Biochemical investigation, including plasma renin, aldosterone and cortisol concentrations and lowdose dexamethasone suppression test, is recommended in ME ~~~
  4. ...adrenocortical carcinoma . Nature Genetics 46 607 – 612 . ( doi:10.1038/ng.2953 ) ↵ Burnichon N , Vescovo L , Amar L , Libe R , de Reynies A , Venisse A , Jouanno E , Laurendeau I , Parfait B , Bertherat J et al. 2011 Integrative genomic analysis reveals somatic mutations in pheochromocytoma and par ~~~
  5. ...adrenocortical carcinoma 10.1530/ERC-17-0095 Elisa Roca1, Alfredo Berruti1, Silviu Sbiera2, Ida Rapa3, Ester Oneda1, Paola Sperone4, Cristina L Ronchi2, Laura Ferrari1, Salvatore Grisanti1, Antonina Germano5, Barbara Zaggia5, Giorgio Vittorio Scagliotti4, Martin Fassnacht2, Marco Volante3, Massimo T ~~~
  6. ...adrenocortical carcinoma cells. Endocrine 52 664–677. (doi:10.1007/s12020-015-0818-0) Del Basso De Caro M, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM, Colao A, Pettinato G & Cappabianca P 2016 Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic an ~~~
  7. ...adrenocortical carcinoma secreting IGF2 not responding to everolimus was recently reported by Korevaar and coworkers (Korevaar  et  al. 2014). It appears that either IGF2 does not cause hypoglycaemia by activation of the insulin receptor, which is improbable, or that the mode of action of everolimus ~~~
  8. ...adrenocortical carcinoma reported to be having a component of adipose tissue ( Izumi et al . 2003 , Heye et al . 2005 , Egbert et al . 2010 ). The tumours were noted in left adrenal, functional and in male patients. One of them is a myxoid variant of adrenocortical carcinoma ( Izumi et al . 2003 ). ~~~
  9. ...adrenocortical carcinoma (ACC) is limited by heterogeneous tumor response and adverse effects. Recently, we demonstrated anti-tumor activity of LEDP-M (etoposide, liposomal doxorubicin, liposomal cisplatin, mitotane), a liposomal variant of EDP-M (etoposide, doxorubicin, cisplatin, mitotane). To imp ~~~
  10. ...adrenocortical carcinoma f biomarker f DNA methylation f epigenetics f IGF2 728Research S G Creemers et al. Methylation of IGF2 regulatory regions in ACCs DOI: 10.1530/ERC-16-0266 © 2016 Society for Endocrinology Printed in Great Britain Published by Bioscientifica ~~~
For checked items